Cargando…
Formula PSORI-CM01 eliminates psoriasis by inhibiting the expression of keratinocyte cyclin B2
BACKGROUND: Psoriasis is a chronically recurrent inflammatory skin disease, modern medicine could achieve good therapeutic effect, but these treatments led to recurrence of the psoriasis, more severe symptoms due to damaging skin barrier. Traditional Chinese medicine is a useful alternative therapie...
Autores principales: | Wei, Jian-an, Han, Ling, Lu, Chuan-jian, Zhao, Rui-zhi, Sun, Jing, Lu, Yue, Lin, Han-jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966758/ https://www.ncbi.nlm.nih.gov/pubmed/27473420 http://dx.doi.org/10.1186/s12906-016-1234-6 |
Ejemplares similares
-
Identification and Quantitative Characterization of PSORI-CM01, a Chinese Medicine Formula for Psoriasis Therapy, by Liquid Chromatography Coupled with an LTQ Orbitrap Mass Spectrometer
por: Chen, Shao-Dan, et al.
Publicado: (2015) -
Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis In Vitro and In Vivo
por: Lu, Yue, et al.
Publicado: (2021) -
PSORI-CM02 Formula Increases CD4+ Foxp3+ Regulatory T Cell Frequency and Ameliorates Imiquimod-Induced Psoriasis in Mice
por: Chen, Haiming, et al.
Publicado: (2018) -
Corrigendum: PSORI-CM02 Formula Increases CD4+ Foxp3+ Regulatory T Cell Frequency and Ameliorates Imiquimod-Induced Psoriasis in Mice
por: Chen, Haiming, et al.
Publicado: (2020) -
Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial
por: Yao, Dan-Ni, et al.
Publicado: (2016)